![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Standard oral cancer therapy generally includes a combination of surgery with chemotherapy and/or radiotherapy. This treatment paradigm has not changed in some time. In this paper, we propose a chemopreventive nanodiamond platform for the delivery of celecoxib (Celebrex) to oral cancer lesions. This innovative platform allows for sustained drug release under physiological conditions, potentially enhancing chemopreventive efficacy of celecoxib without the physical and toxicological damage associated with conventional means of drug delivery.
Additional information
Notes on contributors
Albert Yen
Albert Yen, BS, is in the department of bioengineering, Henry Samueli School of Engineering and Applied Science at the University of California, Los Angeles.
Conflict of Interest Disclosure: None reported.
Kangyi Zhang
Kangyi Zhang, PhD, is in the division of oral biology and medicine at the University of California, Los Angeles, School of Dentistry.
Conflict of Interest Disclosure: None reported.
Giulia Daneshgaran
Giulia Daneshgaran, BS, is in the department of integrative biology and physiology at the University of California, Los Angeles.
Conflict of Interest Disclosure: None reported.
Ho-Joong Kim
Ho-Joong Kim, PhD, is in the department of chemistry at Chosun University in Gwangju, Republic of Korea.
Conflict of Interest Disclosure: None reported.
Dean Ho
Dean Ho, PhD, is a professor in the division of oral biology and medicine and department of bioengineering and is co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the University of California, Los Angeles.
Conflict of Interest Disclosure: None reported.